| Followers | 19 |
| Posts | 6623 |
| Boards Moderated | 1 |
| Alias Born | 05/23/2019 |
Sunday, May 24, 2026 12:42:51 PM
WQLF SAYS: CV SCIENCES will be able to payback a similar loan from Streeterville Capital and net $900,000 and utilizing $100,000 of Cash on hand in order to acquire Extract Lab. CV SCIENCES was able to payback Streeterville Capital $1,050,000 in 2025. It appears that CV SCIENCES was able to repay the loan payments on a weekly basis on time, and therefore, it wasn't the reason for the debt for equity swap. I believe that Streeterville Capital decided to take on the debt for equity swap in order to make a new similar loan to CV SCIENCES in order to Acquire Extract Labs in a Cash offer. IMHO Have Mercy WQLF ahoooooo
Repayment of note payable $1,050,000 in 2025
Repayment of note payable $622,000 in 2024
Q:How much did cv SCIENCES pay Streeterville Capital for outstanding loans in 2025 - Google Search
Ai Generated:
https://www.google.com/search?q=How+much+did+cv+SCIENCES+pay+Streeterville+Capital+for+outstanding+loans+in+2025&oq=How+much+did+cv+SCIENCES+pay+Streeterville+Capital+for+outstanding+loans+in+2025&gs_lcrp=EgZjaHJvbWUyBggAEEUYOdIBCTQwMzQ2ajBqNKgCAbACAQ&client=ms-android-motorola-rvo3&sourceid=chrome-mobile&ie=UTF-8#lfId=ChxjMe
Repayment of note payable $1,050,000 in 2025
Repayment of note payable $622,000 in 2024
Q:How much did cv SCIENCES pay Streeterville Capital for outstanding loans in 2025 - Google Search
Ai Generated:
https://www.google.com/search?q=How+much+did+cv+SCIENCES+pay+Streeterville+Capital+for+outstanding+loans+in+2025&oq=How+much+did+cv+SCIENCES+pay+Streeterville+Capital+for+outstanding+loans+in+2025&gs_lcrp=EgZjaHJvbWUyBggAEEUYOdIBCTQwMzQ2ajBqNKgCAbACAQ&client=ms-android-motorola-rvo3&sourceid=chrome-mobile&ie=UTF-8#lfId=ChxjMe
Bullish
Recent CVSI News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 08:10:09 PM
- CV Sciences, Inc. Reports First Quarter-End 2026 Financial Results • ACCESS Newswire • 05/14/2026 08:00:00 PM
- CV Sciences, Inc. To Announce First Quarter 2026 Results On May 14, 2026 • ACCESS Newswire • 05/12/2026 10:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/10/2026 08:04:10 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/26/2026 09:14:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 08:06:03 PM
- CV Sciences, Inc. Reports Fiscal Year-End 2025 Financial Results • ACCESS Newswire • 03/26/2026 08:00:00 PM
- CV Sciences, Inc. To Announce Year End and Fourth Quarter 2025 Results On March 26, 2026 • ACCESS Newswire • 03/24/2026 09:00:00 PM
- CV Sciences Announces Successful Debt Restructuring Designed to Strengthen Financial Position and Fuel Future Growth • ACCESS Newswire • 03/10/2026 09:00:00 PM
- CV Sciences Launches EMPOWR: A Plant-Based Protein + Creatine Formula Designed for Total Wellness • ACCESS Newswire • 02/26/2026 01:30:00 PM
- CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD • ACCESS Newswire • 12/23/2025 12:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 10:19:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 09:04:08 PM
- CV Sciences, Inc. Reports Third Quarter 2025 Financial Results • ACCESS Newswire • 11/13/2025 09:00:00 PM
- CV Sciences, Inc. to Announce Third Quarter 2025 Results on November 13, 2025 • ACCESS Newswire • 11/10/2025 11:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/10/2025 09:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2025 08:24:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2025 09:23:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2025 08:01:09 PM
